Pediatrics · Medical Literature
Effects of Bifidobacterium animalis Subsp. Lactis CP-9 on Gut Microbiota and Immune Functions in Healthy Infants.
Abstract
Infancy represents a critical period for growth and development, during which the gut microbiota and its metabolites play essential roles in nutrient absorption and maintaining health. Therefore, it is of great significance to evaluate the safety and gut microbiota-modulating effects of specific probiotics in healthy infants. This study aimed to investigate the effect of Bifidobacterium animalis subsp. lactis CP-9 strain (CP-9) on healthy infants aged 6 to 36 months and its relationship with growth patterns and multidimensional indicators. In this randomized, double-blind, placebo-controlled trial, healthy infants were randomly assigned to receive CP-9 or placebo for 3 months. Safety, growth parameters, complete blood counts (CBC), immunological markers and faecal microbiota were assessed before and after the intervention. All infants exhibited age-appropriate growth in height and head circumference during the study. The CP-9 strain significantly increased gut Bifidobacterium abundance and regulated the microbiota-mediated polyunsaturated fatty acids biosynthesis pathway. Haematological and systemic inflammatory markers remained within normal ranges and no treatment-related adverse changes were detected during the 3-month intervention period. Moreover, CP-9 improved stool characteristics and gastrointestinal tolerability, with no increase in the incidence of respiratory allergies, skin allergies, respiratory infections, or fever, which further confirmed its safety. These findings suggested that CP-9 supplementation resulted in significant enrichment of Bifidobacterium, a beneficial gut bacterium and had no detectable adverse effects on the measured physiological parameters. Consequently, the intervention raised no detectable safety concerns in healthy infants under the conditions of this study. Given this, CP-9 is a probiotic that does not show any obvious short-term safety signals for infants aged 6 to 36 months.
Clinical relevance
This randomized, double-blind, placebo-controlled trial addresses a critical gap in pediatric probiotic safety data by rigorously evaluating Bifidobacterium animalis subsp. lactis CP-9 in healthy infants aged 6–36 months — a vulnerable population undergoing rapid gut microbiome establishment. Given the widespread and often evidence-poor commercial use of probiotics in infants, clinicians need strain-specific, age-appropriate safety and efficacy data to guide evidence-based recommendations. This study is clinically timely as it provides multidimensional safety endpoints (hematologic, immunologic, microbiologic, and anthropometric) alongside functional microbiota outcomes.
Key findings
1. Study design: Randomized, double-blind, placebo-controlled trial in healthy infants aged 6–36 months receiving CP-9 or placebo for 3 months; safety, growth parameters, CBC, immunological markers, and fecal microbiota were assessed at baseline and post-intervention. 2. Microbiota modulation: CP-9 supplementation produced a statistically significant increase in gut Bifidobacterium relative abundance compared to placebo; specific effect sizes and confidence intervals were not reported in the abstract. 3. Metabolic pathway regulation: CP-9 significantly regulated the microbiota-mediated polyunsaturated fatty acids (PUFA) biosynthesis pathway, suggesting a functional metabolic benefit beyond simple colonization, though quantitative pathway data were not abstracted. 4. Safety — hematologic and inflammatory markers: All CBC and systemic inflammatory markers remained within age-appropriate normal ranges throughout the 3-month intervention, with no treatment-related adverse hematologic changes detected. 5. Safety — clinical adverse events: No increase in the incidence of respiratory allergies, skin allergies, respiratory infections, or fever was observed in the CP-9 group relative to placebo, supporting short-term clinical safety. 6. Growth and GI tolerability: All enrolled infants demonstrated age-appropriate growth in height and head circumference; CP-9 additionally improved stool characteristics and gastrointestinal tolerability with no quantified difference in adverse GI events reported in the abstract.
Practice implications
Pediatricians and neonatologists may consider CP-9 (Bifidobacterium animalis subsp. lactis CP-9) a candidate probiotic for healthy infants aged 6–36 months, supported by 3-month safety data encompassing hematologic, immunologic, allergic, and anthropometric endpoints with no detected adverse signals. The demonstrated enrichment of Bifidobacterium and upregulation of the PUFA biosynthesis pathway suggest potential benefits for gut microbiome maturation and metabolic health, though clinicians should note that this study evaluated short-term outcomes only and that long-term efficacy and safety data are not yet available. Patient selection should be limited to healthy, term infants in the studied age range, and practitioners should continue individualized risk-benefit assessment for immunocompromised or high-risk neonatal populations, for whom this study's findings are not directly applicable.